Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

Sign Up

  

Colby Pharmaceutical Company is developing novel drugs for treatment of prostate cancer. If you would like to receive regular company updates please fill out the sign up form.

 

Colby values your privacy. Please click to Unsubscribe.

 
Sign up to receive Colby Pharmaceutical Company news and updates 
 
First Name * : Last Name * : Organization * : Category * :
Email * : Phone Number * :
Country * :
City : State : Comments :
Clear Submit